Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: Potential benefit of medium-dose etoposide conditioning

被引：10
作者：
Imamura M. [1 ]
Shigematsu A. [1 ]
机构：
[1] Department of Hematology, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6-5-1, Shiroishi-ku, Sapporo
来源：
Experimental Hematology & Oncology | / 4卷 / 1期
关键词：
Acute lymphoblastic leukemia; Cyclophosphamide; Etoposide; Haploidentical HSCT; Hematopoietic stem cell transplantation; Myeloablative conditioning regimen; Philadelphia chromosome; Reduced-intensity conditioning regimen; Total body irradiation; Tyrosine kinase inhibitor;
D O I：
10.1186/s40164-015-0015-0
中图分类号：
学科分类号：
摘要：
The outcomes of adult acute lymphoblastic leukemia (ALL) patients with chemotherapy or autologous hematopoietic stem cell transplantation (HSCT) are unsatisfactory. Therefore, allogeneic (allo) HSCT has been applied to those patients in first complete remission (CR1), and has shown a long-term survival rate of approximately 50%. In terms of myeloablative conditioning (MAC) regimen, higher dose of cyclophosphamide (CY) and total body irradiation (TBI) (the standard CY+TBI) has been generally applied to allo HSCT. Other MAC regimens such as busulfan-based or etoposide-based regimens have also been used. Among those, medium-dose etoposide (ETP) in addition to the standard CY+TBI conditioning regimen appears to be promising for allo HSCT in adult ALL when transplanted in ALL patients aged under 50years in CR1 and also in CR2, showing an excellent outcome without increasing relapse or transplant-related mortality (TRM) rates. By contrast, reduced-intensity conditioning (RIC) regimens have also been applied to adult ALL patients and favorable outcomes have been obtained; however, relapse and TRM rates remain high. Therefore, an allo HSCT conditioning regimen which deserves further study for adult ALL patients aged under 50years in CR1 and CR2 appears to be medium-dose ETP+CY+TBI and RIC is suitable for patients aged over 50years or for younger patients with comorbid conditions. On the contrary, new therapeutic strategies for adult ALL patients are increasingly utilized with better outcomes; namely, various tyrosine kinase inhibitors for Philadelphia chromosome (Ph)-positive ALL, human leukocyte antigen-haploidentical HSCT, and pediatric-inspired regimens for Ph-negative ALL. Therefore, the optimal treatment modality should be selected considering patient's age, Ph-positivity, donor availability, risk classification, efficacy, and safety. © 2015 Imamura and Shigematsu.
引用
收藏
相关论文
共 75 条
  • [1] Aversa F., Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States, Bone Marrow Transplant, 41, pp. 473-481, (2008)
  • [2] Bachanova V., Marks D.I., Zhang M.-J., Wang H., De Lima M., Aljurf M.D., Et al., Ph+ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease, Leukemia, 28, pp. 658-665, (2014)
  • [3] Bachanova V., Verneris M.R., DeFor T., Brunstein C.G., Weisdorf D.J., Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation, Blood, 113, pp. 2902-2905, (2009)
  • [4] Barrett A.J., Horowitz M.M., Ash R.C., Atkinson K., Gale R.P., Goldman J.M., Et al., Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood, 79, pp. 3067-3070, (1992)
  • [5] Bishop M.R., Logan B.R., Gandham S., Bolwell B.J., Cahn J.Y., Lazarus H.M., Et al., Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research, Bone Marrow Transplant, 41, pp. 635-642, (2008)
  • [6] Blume K.G., Forman S.J., O'Donnell M.R., Doroshow J.H., Krance R.A., Nademanee A.P., Et al., Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies, Blood, 69, pp. 1015-1020, (1987)
  • [7] Blume K.G., Kopecky K.J., Henslee-Downey J.P., Forman S.J., Stiff P.J., LeMaistre C.F., Et al., A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparative regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group Study, Blood, 81, pp. 2187-2193, (1993)
  • [8] Borgmann A., Zinn C., Hartmann R., Herold R., Kaatsch P., Escherich G., Et al., Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood, Eur J Cancer, 44, pp. 257-268, (2005)
  • [9] Brown R.A., Herzig R.H., Wolff S.N., Frei-Lahr D., Pineiro L., Bolwell R.A., Et al., High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy, Blood, 76, pp. 473-479, (1990)
  • [10] Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J.J., Et al., Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation: IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT), Blood, 95, pp. 3702-3709, (2000)
12345678